New central body and more cash for UK medical R&D (research and development):
This article was originally published in Clinica
Executive Summary
This week's UK public spending review has been welcomed by the healthcare technology industries for its focus on science. Of note is the increase in R&D spending compared with GDP, from 1.86% to 2.5% by 2014. The BioIndustry Association welcomed this and other measures, some of which were recommended in the sector's framework report, Bioscience 2015. This includes pledges to improve clinical research infrastructure, backed by the creation of the UK Clinical Research Collaboration (UKCRC). Its launch, last week, came with a £24m ($44.5m) initial research budget. A further £7m will go to equipping infrastructure. Further reviews of clinical research funding are promised before the 2006 spending review.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.